The FDA Has Granted Fast Track Designation To Astria Therapeutics' STAR-0215 For Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Fast Track Designation to Astria Therapeutics' STAR-0215 for Hereditary Angioedema. STAR-0215 is currently being evaluated in the ALPHA-STAR clinical trial, with initial proof-of-concept results expected in mid-2024.
July 20, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astria Therapeutics' STAR-0215 has received Fast Track Designation from the FDA. This could potentially expedite the drug's development and review process.
Fast Track Designation by the FDA is a significant milestone for any drug development process. It allows for expedited review and development, which could potentially lead to earlier approval and market entry. This is likely to have a positive impact on Astria Therapeutics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100